Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07933341

LH-Guided Recombinant LH Supplementation in Women Undergoing IVF/ICSI

Sponsor: Stella Maris Women and Children Hospital

View on ClinicalTrials.gov

Summary

The goal of this observational study is to evaluate the relationship between luteinizing hormone (LH)-guided recombinant LH supplementation and IVF outcomes in women aged 21-45 years undergoing their first IVF/ICSI cycle using a gonadotropin-releasing hormone (GnRH) antagonist protocol. The main questions it aims to answer are: * Is LH-guided recombinant LH supplementation associated with a higher number of good-quality blastocysts? * Is LH-guided recombinant LH supplementation associated with a higher clinical pregnancy rate? Researchers will compare two groups of women: Group A (LH-Guided Supplementation): Women with serum LH levels below 1.2 mIU/mL on menstrual cycle day 2 or stimulation day 5 (corresponding to menstrual cycle day 6) who received recombinant LH supplementation at 75 IU/day until ovulation triggering. Group B (No LH Supplementation): Women with serum LH levels of 1.2 mIU/mL or higher at both assessments who underwent standard ovarian stimulation without recombinant LH supplementation.

Official title: Day-6 LH-Guided Recombinant LH Supplementation and IVF Outcomes in GnRH Antagonist Cycles: A Retrospective Cohort Study

Key Details

Gender

FEMALE

Age Range

21 Years - 45 Years

Study Type

OBSERVATIONAL

Enrollment

395

Start Date

2023-01-01

Completion Date

2023-12-31

Last Updated

2026-11-12

Healthy Volunteers

Not specified

Locations (1)

RSIA Stella Maris

Medan, North Sumatra, Indonesia